June 3, 2024

Merck KGaA to acquire Mirus Bio

Key Points

Key points are not available for this paper at this time.

Abstract

MilliporeSigma, the North American life sciences business of the German company Merck KGaA, has agreed to acquire Mirus Bio for 600 million. Spun off from the University of Wisconsin in 1995, the firm was bought by Wisconsin-based Gamma Biosciences in 2021. Mirus Bio makes transfection reagents, which are used as vehicles to inject viral vector-based gene therapies into cells. The companies expect to complete the deal in the third quarter of this year.

Mark Helpful

Bookmark

Relay

Cite This Study

Aayushi Pratap (Mon,) studied this question.

synapsesocial.com/papers/68e66728b6db6435875f362b https://doi.org/https://doi.org/10.1021/cen-10217-buscon13

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Mirador launches with $400 million2024
2P0953 A panel of 11 genes from colon and rectum biopsies in the LUCENT-URGE study shows utility for predicting responses to mirikizumab treatment of Ulcerative Colitis2026
3P0563 Mirikizumab Demonstrated Sustained and Durable Long-Term Efficacy and Favorable Safety in Week 52 Endoscopic Responders with Crohn’s disease: 3-year VIVID-2 Open-Label Extension Interim Results2026
4P1103 Mirikizumab demonstrated high treatment persistence and effectiveness in a real-world retrospective study in Canadian adult patients with moderately to severely active Ulcerative Colitis2026
5DOP120 Mirikizumab demonstrates consistent and sustained disease clearance at four years of treatment in patients with moderately to severely active Ulcerative Colitis2026

Mark Helpful

Bookmark

Relay